News & Updates

Multiple biosimilar infliximab (IFX) switching among patients with inflammatory bowel disease (IBD) does not seem to give rise to disease flares at 12 months compared to those who continued using IFX originator or those on single IFX biosimilar switch, a study has shown.

Adopting a more conservative approach to venous thromboembolism (VTE) prophylaxis results in reduced rates of wound hematomas, with no increase in postpartum VTE, according to a recent study presented at SMFM 2024.